본문 바로가기
KERD
논문KCI 등재

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Jia-Horng Kao|Cheng-Hao Tseng|Yao-Chun Hsu
대한간학회 (The korean Association for the Study of the Liver)|2023.10|Clinical and Molecular Hepatology|제29권 제4호|pp. 869-890

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Patient safetyAntiviral agentsHepatitis B surface antigensHepatitis B virus infection

초록

Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at seroclearance of the hepatitis B surface antigen (HBsAg). As an alternative strategy, finite NA therapy without the prerequisite of HBsAg seroclearance has been proposed to allow treatment cessation in patients with sustained undetectable HBV viremia for two to three years. However, reactivation of viral replication almost always follows NA withdrawal. Whereas HBV reactivation might facilitate HBsAg seroclearance in some, it could lead to serious acute flare-ups in a certain proportion of patients. Occurrence and consequences of NA withdrawal flares are complicated with various factors involving the virus, host, and treatment. Accurate risk prediction for severe flares following NA cessation is essential to ensure patient safety. The risks of life-threatening flares in patients who discontinued NA according to the stopping rules of current guidelines or local reimbursement policies have recently been quantitatively estimated in large-scale studies, which also provided empirical evidence to help identify vulnerable patients at risk of devastating outcomes. Moreover, risk predictors were further explored and validated to hopefully aid in patient selection and management. In this narrative review with a focus on patient safety, we summarize and discuss current literature on the incidence of severe flares following NA cessation, risk stratification for candidate selection, rules of posttreatment monitoring, and indications for treatment resumption. We also share our thoughts on the limitations of existing knowledge and suggestions for future research.

Abstract

Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at seroclearance of the hepatitis B surface antigen (HBsAg). As an alternative strategy, finite NA therapy without the prerequisite of HBsAg seroclearance has been proposed to allow treatment cessation in patients with sustained undetectable HBV viremia for two to three years. However, reactivation of viral replication almost always follows NA withdrawal. Whereas HBV reactivation might facilitate HBsAg seroclearance in some, it could lead to serious acute flare-ups in a certain proportion of patients. Occurrence and consequences of NA withdrawal flares are complicated with various factors involving the virus, host, and treatment. Accurate risk prediction for severe flares following NA cessation is essential to ensure patient safety. The risks of life-threatening flares in patients who discontinued NA according to the stopping rules of current guidelines or local reimbursement policies have recently been quantitatively estimated in large-scale studies, which also provided empirical evidence to help identify vulnerable patients at risk of devastating outcomes. Moreover, risk predictors were further explored and validated to hopefully aid in patient selection and management. In this narrative review with a focus on patient safety, we summarize and discuss current literature on the incidence of severe flares following NA cessation, risk stratification for candidate selection, rules of posttreatment monitoring, and indications for treatment resumption. We also share our thoughts on the limitations of existing knowledge and suggestions for future research.

참고문헌 (117)

  1. "Fact sheets/Detail/Hepatitis B"[URL]
  2. Lok AS, "Antiviral therapy for chronic hepatitis B viral infection in adults : A systematic review and meta-analysis", Hepatology, 63, pp.284~306 (2016)
  3. Wu CY, "Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B : a nationwide cohort study", Gastroenterology, 147, pp.143~151 (2014)
  4. Su TH, "Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients", Liver Int, 36, pp.1755~1764 (2016)
  5. Liu Y, "No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg-patients with chronic hepatitis B after 8years of treatment", J Viral Hepat, 24, pp.68~74 (2017)
  6. Werle-Lapostolle B, "Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy", Gastroenterology, 126, pp.1750~1758 (2004)
  7. Grudda T, "Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment", J Clin Invest, 132, pp.e161818~ (2022)
  8. Seto WK, "Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B : a multicentre prospective study", Gut, 64, pp.667~672 (2015)
  9. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
  10. Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
  11. European Association for the Study of the Liver, "EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
  12. Yip TC, "Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients", J Hepatol, 68, pp.63~72 (2018)
  13. Hsu YC, "Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B", J Infect Dis, 224, pp.1890~1899 (2021)
  14. Jeng WJ, "Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B", Hepatology, 68, pp.425~434 (2018)
  15. Kim GA, "HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B : clinical outcomes and durability", Gut, 63, pp.1325~1332 (2014)
  16. Ford N, "Adherence to nucleos(t)ide analogue therapies for chronic hepatitis B infection : A systematic review and metaanalysis", Hepatol Commun, 2, pp.1160~1167 (2018)
  17. Madeddu G, "Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B", Sci Rep, 10, pp.2014~ (2020)
  18. Liaw YF, "Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B : an emerging paradigm shift", Hepatol Int, 13, pp.665~673 (2019)
  19. Hadziyannis SJ, "Sustained responses and loss of HBsAg in HBeAgnegative patients with chronic hepatitis B who stop long-term treatment with adefovir", Gastroenterology, 143, pp.629~636 (2012)
  20. Lampertico P, "Less can be more : A finite treatment approach for HBeAg-negative chronic hepatitis B", Hepatology, 68, pp.397~400 (2018)
  21. Berg T, "The times they are a-changing-A refined proposal for finite HBV nucleos(t)ide analogue therapy", J Hepatol, 75, pp.474~480 (2021)
  22. Reijnders JG, "Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B", Gastroenterology, 139, pp.491~498 (2010)
  23. Tseng TC, "Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation", J Infect Dis, 206, pp.1521~1531 (2012)
  24. World Health Organization, "Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection", World Health Organization, ~ (2015)
  25. Coffin CS, "Management of hepatitis B virus infection : 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada", Can Liver J, 1, pp.156~217 (2018)
  26. Wang G, "Guidelines for prevention and treatment of chronic hepatitis B", J Clin Transl Hepatol, 9, pp.769~791 (2021)
  27. Drafting Committee for Hepatitis Management Guidelines, "Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection : 2019 update", Hepatol Res, 50, pp.892~923 (2020)
  28. The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 28(2), pp.276~331 (2022), 대한간학회
  29. Westin J, "Management of hepatitis B virus infection, updated Swedish guidelines", Infect Dis(Lond), 52, pp.1~22 (2020)
  30. Tabak F, "Diagnosis, management and treatment of hepatitis B virus infection : Turkey 2017 Clinical Practice Guidelines", Turk J Gastroenterol, 28(Suppl 2), pp.73~83 (2017)
  31. Van Hees S, "Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes", Aliment Pharmacol Ther, 47, pp.1170~1180 (2018)
  32. Hall SAL, "Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B : a meta-analysis", Gut, 71, pp.1629~1641 (2022)
  33. Hirode G, "Incidence of hepatic decompensation after nucleos(t)ide analog withdrawal: Results from a large, international, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B Study)", Am J Gastroenterol (2023)[DOI]
  34. Hsu YC, "Severe acute exacerbation after cessation of nucleos(t)ide analog for chronic hepatitis B : A real-world study of routine practice", Clin Gastroenterol Hepatol, 20, pp.1413~1415 (2022)
  35. Liu YC, "Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies", Liver Int, 42, pp.551~560 (2022)
  36. Chang ML, "Hepatitis B flares in chronic hepatitis B : pathogenesis, natural course, and management", J Hepatol, 61, pp.1407~1417 (2014)
  37. Ghany MG, "Serum alanine aminotransferase flares in chronic hepatitis B infection : the good and the bad", Lancet Gastroenterol Hepatol, 5, pp.406~417 (2020)
  38. Perrillo RP, "Acute flares in chronic hepatitis B : the natural and unnatural history of an immunologically mediated liver disease", Gastroenterology, 120, pp.1009~1022 (2001)
  39. Paul S, "Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy : A systematic review and meta-analysis", Ann Intern Med, 164, pp.30~40 (2016)
  40. Pauly MP, "Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists", Clin Gastroenterol Hepatol, 16, pp.1964~1973 (2018)
  41. Hsu YC, "Severe hepatitis flare and related mortality after discontinuation of oral antiviral treatment in patients with chronic hepatitis b : A population-based study", Hepatology, 74, pp.18A~ (2021)
  42. Hsu YC, "Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B : challenges and opportunities", Gut, 71, pp.1238~1240 (2022)
  43. Tseng CH, "Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B : A systematic review and meta-analysis", JHEP Rep, 5, pp.100617~ (2022)
  44. Ma TL, "Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment", PLoS One, 14, pp.e0222221~ (2019)
  45. Sonneveld MJ, "Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: A multicenter study (CREATE).", Clin Gastroenterol Hepatol, 20, pp.e784~e793 (2022)
  46. Wong GL, "The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B", Liver Int, 40, pp.549~557 (2020)
  47. Lai CY, "Cessation of nucleos(t)ide analogue therapy in non-Cirrhotic hepatitis B patients with prior severe acute exacerbation", J Clin Med, 10, pp.4883~ (2021)
  48. Hirode G, "Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B:An international, multicenter, multiethnic cohort (RETRACT-B study).", Gastroenterology, 162, pp.757~771 (2022)
  49. Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B : a 2012 update", Hepatol Int, 6, pp.531~561 (2012)
  50. Höner Zu Siederdissen C, "Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B", J Infect Dis, 214, pp.1492~1497 (2016)
  51. Rinker F, "Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B", J Hepatol, 69, pp.584~593 (2018)
  52. van Bömmel F, "Risks and benefits of discontinuation of nucleos(t)ide analogue treatment : A Treatment concept for patients with HBeAg-negative chronic hepatitis B", Hepatol Commun, 5, pp.1632~1648 (2021)
  53. Kao JH, "Nucleos(t)ide analogues in patients with chronic hepatitis B : to stop or not to stop?", Gut, 68, pp.2105~2106 (2019)
  54. Hsu YC, "Association between serum level of hepatitis B surface antigen at end of entecavir therapy and risk of relapse in E antigennegative patients", Clin Gastroenterol Hepatol, 14, pp.1490~1498 (2016)
  55. Chen CH, "Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection", Clin Gastroenterol Hepatol, 13, pp.1984~1992 (2015)
  56. Chen CH, "The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment", J Hepatol, 61, pp.515~522 (2014)
  57. Wang CC, "Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg", Am J Gastroenterol, 111, pp.1286~1294 (2016)
  58. Liu J, "The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian patients with chronic hepatitis B : A systematic review", Hepatology, 70, pp.1045~1055 (2019)
  59. Tseng TN, "Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU", mL, 2020, pp.18, 2803~2812
  60. Maasoumy B, "Hepatitis B core-related antigen(HBcrAg)levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D", Clin Microbiol Infect, 21, pp.606~ (2015)
  61. Chen EQ, "Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B", Sci Rep, 7, pp.173~ (2017)
  62. Hsu YC, "Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk", Aliment Pharmacol Ther, 49, pp.107~115 (2019)
  63. Huang PY, "The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients", J Viral Hepat, 28, pp.1141~1149 (2021)
  64. Seto WK, "Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation", Gut, 70, pp.775~783 (2021)
  65. Liao G, "Hepatitis B core-related antigen is a biomarker for off-treatment relapse after long-term nucleos(t)ide analog therapy in patients with chronic hepatitis B", Int J Gen Med, 14, pp.4967~4976 (2021)
  66. Papatheodoridi M, "Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B", J Viral Hepat, 27, pp.118~126 (2020)
  67. Jeng WJ, "Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients", Hepatology, 58, pp.1888~1896 (2013)
  68. Kuo MT, "Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir", Aliment Pharmacol Ther, 49, pp.218~228 (2019)
  69. Chiu SM, "Associations of HBV genotype B vs C infection with relapse after cessation of entecavir or tenofovir therapy", Clin Gastroenterol Hepatol, 18, pp.2989~2997 (2020)
  70. Cheng HR, "Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAgnegative patients", Hepatol Int, 15, pp.582~592 (2021)
  71. Su TH, "Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy", J Infect Dis, 217, pp.1193~1201 (2018)
  72. Tseng CH, "Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B", J Formos Med Assoc, 117, pp.915~921 (2018)
  73. Chi H, "Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy", Clin Gastroenterol Hepatol, 17, pp.182~191 (2019)
  74. Kranidioti H, "Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B", J Viral Hepat, 26, pp.697~709 (2019)
  75. Sonneveld MJ, "Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels", J Hepatol, 76, pp.1042~1050 (2022)
  76. Tong S, "Overview of hepatitis B viral replication and genetic variability", J Hepatol, 64(1 Suppl), pp.S4~S16 (2016)
  77. Maini MK, "Direct ex vivo analysis of hepatitis B virus-specific CD8(+)T cells associated with the control of infection", Gastroenterology, 117, pp.1386~1396 (1999)
  78. Maini MK, "The role of virus-specific CD8(+)cells in liver damage and viral control during persistent hepatitis B virus infection", J Exp Med, 191, pp.1269~1280 (2000)
  79. Iannacone M, "Immunobiology and pathogenesis of hepatitis B virus infection", Nat Rev Immunol, 22, pp.19~32 (2022)
  80. Rivino L, "Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation", J Clin Invest, 128, pp.668~681 (2018)
  81. García-López M, "Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients", J Hepatol, 74, pp.1064~1074 (2021)
  82. Boni C, "Characterization of hepatitis B virus(HBV)-specific Tcell dysfunction in chronic HBV infection", J Virol, 81, pp.4215~4225 (2007)
  83. Peña-Asensio J, "Model to predict ontreatment restoration of functional HBV-specific CD8+ cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B", Aliment Pharmacol Ther, 55, pp.1545~1559 (2022)
  84. Ito K, "Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection", Clin Infect Dis, 38, pp.490~495 (2004)
  85. Chi H, "Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B", Aliment Pharmacol Ther, 41, pp.867~876 (2015)
  86. Jeng WJ, "Clinical relapse after cessation of tenofovir therapy in hepatitis B e antigen-negative patients", Clin Gastroenterol Hepatol, 14, pp.1813~1820 (2016)
  87. Papatheodoridis G, "Discontinuation of oral antivirals in chronic hepatitis B : A systematic review", Hepatology, 63, pp.1481~1492 (2016)
  88. Choi HSJ, "Differential relapse patterns after discontinuation of entecavir vs tenofovir disoproxil fumarate in chronic hepatitis B", Clin Gastroenterol Hepatol (2022)[DOI]
  89. Höner Zu Siederdissen C, "Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e Antigen-negative patients", J Infect Dis, 218, pp.1480~1484 (2018)
  90. Drafting Committee for Hepatitis Management Guidelines, "JSH Guidelines for the Management of Hepatitis B Virus Infection", Hepatol Res, 44Suppl(S1), pp.1~58 (2014)
  91. Kaewdech A, "Clinical utility of SCALE-B to predict hepatitis B virus relapse, hepatitis B surface antigen loss after antiviral cessation in Asian patients after 2-year follow-up", Front Med(Lausanne), 9, pp.859430~ (2022)
  92. Kao JH, "APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients", Hepatol Int, 15, pp.833~851 (2021)
  93. Chen CH, "HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide", Dig Liver Dis (2023)[DOI]
  94. Liem KS, "Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B", J Viral Hepat, 29, pp.986~993 (2022)
  95. Hsu YC, "Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy", J Gastroenterol Hepatol, 32, pp.1512~1519 (2017)
  96. Liu YC, "The role of offtherapy viral kinetics in the timing and severity of flares in hepatitis B e antigen-negative patients", Clin Gastroenterol Hepatol (2022)[DOI]
  97. Chien NH, "Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy", BMC Gastroenterol, 17, pp.154~ (2017)
  98. Chu CM, "Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma", J Gastroenterol Hepatol, 15(Suppl), pp.E25~E30 (2000)
  99. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
  100. Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
  101. Hsu YC, "Application of risk scores for hepatocellular carcinoma in patients with chronic hepatitis B : Current status and future perspective", Semin Liver Dis, 41, pp.285~297 (2021)
  102. Berg T, "Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients-FINITE study", J Hepatol, 67, pp.918~924 (2017)
  103. van Bömmel F, "Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients : Results of the Stop-NUC trial", J Hepatol, 73, pp.S118~S119 (2020)
  104. Liem KS, "Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B : results from a randomised controlled trial(Toronto STOP study)", Gut, 68, pp.2206~2213 (2019)
  105. Hall SAL, "Stopping nucleot(s)ide analogues in noncirrhotic HBeAg-negative chronic hepatitis B patients : HBsAg loss at 96weeks is associated with low baseline HBsAg levels", Aliment Pharmacol Ther, 56, pp.310~320 (2022)
  106. Papatheodoridis GV, "DARING-B : discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B", Antivir Ther, 23, pp.677~685 (2018)
  107. Xia M, "Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment", Aliment Pharmacol Ther, 54, pp.709~714 (2021)
  108. Xie Y, "HBeAg-positive patients with HBsAg <100 IU", mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation, 2021, pp.56, 856~867
  109. Hsu YC, "Pretreatment viral DNA stratifies mortality risk in patients receiving antiviral therapy for severe acute exacerbation of chronic hepatitis B", Antivir Ther, 18, pp.221~228 (2013)
  110. Chen CH, "Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation", J Hepatol, 60, pp.1127~1134 (2014)
  111. Liaw YF, "HBsAg kinetics in retreatment decision for off-therapy hepatitis B Flare in HBeAg-negative patients", Gastroenterology, 154, pp.2280~2281 (2018)
  112. Chien RN, "Re-treatment for severe hepatitis flare in HBeAg-negative chronic hepatitis B : An appraisal with combined HBsAg", ALT kinetics, 2020, pp.27, 544~547
  113. McDonald CJ, "Medical heuristics : the silent adjudicators of clinical practice", Ann Intern Med, 124(1 Pt 1), pp.56~62 (1996)
  114. Papatheodoridis GV, "Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B", Hepatology, 68, pp.415~424 (2018)
  115. Guyatt GH, "GRADE guidelines : 4. Rating the quality of evidence--study limitations(risk of bias)", J Clin Epidemiol, 64, pp.407~415 (2011)
  116. Gerstein HC, "Real-world studies no substitute for RCTs in establishing efficacy", Lancet, 393, pp.210~211 (2019)
  117. Agarwal K, "A case of HBV-induced liver failure in the REEF-2 phase II trial : Implications for finite treatment strategies in HBV ‘cure’", J Hepatol, 77, pp.245~248 (2022)

관련 논문AI추천

Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessationCheng-Hao Tseng, Chieh-Chang Chen, Jaw-Town Lin, Jia-Ling Wu, Mindie H. Nguyen, Tzeng-Huey Yang, Tzu-Haw Chen, Yao-Chun Hsu, Yi-Ling Wu, Ying-Nan Tsai, Yu-Jen Fang대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제1호Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0Apichat Kaewdech, Di Wu, Fengmin Lu, Fu-sheng Wang, Guiqiang Wang, Hong Ren, Jia-Horng Kao, Junqi Niu, Man-Fung Yuen, Meifang Han, Motoyuki Otsuka, Patrick T.F. Kennedy, Paul Yien Kwo, Peng Hu, Qin Ning, Sainan Shu, Sang Hoon Ahn, Teerha Piratvisuth, Weiming Yan, Wenhong Zhang, Wenhui Li, Xiaojing Wang, Yasuhito Tanaka, Young-Suk Lim, Zhenghong Yuan, Zhiliang Gao대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Management of Chronic Hepatitis B with Nucleoside or Nucleotide Analogues: A Review of Current Guidelines유병철, 최문석거트앤리버 소화기연관학회협의회 · Gut and Liver2010 · 제4권 제1호Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients김기찬, 김순선, 김영집, 이다미, 정재연, 조성원, 황선혁대한간학회 · Clinical and Molecular Hepatology2013 · 제19권 제3호The role of different viral biomarkers on the management of chronic hepatitis BJames Fung, Lung-Yi Mak, Man-Fung Yuen, Rex Wan-Hin Hui, Wai Kay Seto대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stopDong Hyun Sinn, Eileen L. Yoon, Hana Park, Hyung Joon Yim, Hyun Woong Lee, Jeong-Hoon Lee, Ji Hoon Kim, Jung Hyun Kwon, Jun Yong Park, Sae Hwan Lee대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제4호

이 간행물의 다른 논문 (22건)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernityJoon Ho Moon, 김원, Gi-Ae Kimpp. 831-843Waiting for the changes after the adoption of steatotic liver disease전대원, Eileen L. Yoonpp. 844-850Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapyTakako Inoue, Yasuhito Tanaka, Takehisa Watanabepp. 851-868Hepatorenal syndrome: Current concepts and future perspectivesChan-Young Jung, Jai Won Changpp. 891-908The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatmentStephen L. Chan, Landon L. Chanpp. 909-923
원문 보기